SELECTION Positive For Gilead/Galapagos’s Filgotinib In UC But Will It Be Enough To Compete?
Ulcerative Colitis Market Is Crowded
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
